Related Experiment Video
Updated: May 29, 2026
05:42
Isolation of Cells with Morphological and Spatial Information from Oral Submucous Fibrosis Samples by Laser Capture Microdissection
Published on: August 11, 2023
DNA polymorphisms and tissue cyclooxygenase-2 expression in oral lichen planus: a case-control study
R M Abdel Hay1, M M Fawzy, D Metwally
1Department of Dermatology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Journal of the European Academy of Dermatology and Venereology : JEADV
|September 20, 2011
Summary
This study found no significant association between the cyclooxygenase-2 (COX-2) 765G>C gene polymorphism and oral lichen planus (OLP). Increased prostaglandin E2 levels in OLP patients suggest inflammation, but the specific gene variation does not appear to be a risk factor.
Area of Science:
- Genetics and Molecular Biology
- Oral Pathology
- Cancer Research
Background:
- Oral lichen planus (OLP) is a chronic inflammatory condition with precancerous potential.
- Cyclooxygenase-2 (COX-2) expression is investigated for its role in oral squamous cell carcinoma development.
- Single nucleotide polymorphisms (SNPs) are studied for their contribution to disease predisposition.
Purpose of the Study:
- To investigate the association between the COX-2 765G>C gene polymorphism and OLP.
- To examine the relationship between tissue COX-2 expression and OLP development.
Main Methods:
- Study included 50 OLP patients and 50 healthy controls.
- Tissue prostaglandin E2 (PGE2) levels were measured to assess COX-2 activity.
- COX-2 765G>C gene polymorphism was analyzed using RT-PCR and RFLP.
Main Results:
- OLP patients exhibited significantly higher mean PGE2 levels compared to controls.
- No significant differences in genotype distribution or allele frequency of COX-2 765G>C were found between groups.
- The COX-2 765G>C polymorphism showed no statistically significant association with OLP risk.
Conclusions:
- Genetic variations in the COX-2 gene are unlikely to be a primary factor in the etiology of OLP.
- This study is the first to report on the COX-2 -765G>C gene polymorphism and OLP risk.
- Further research with larger sample sizes is recommended to validate these findings.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...